Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark.
Open Access
- 1 August 1993
- journal article
- Published by Wiley
- Vol. 36 (2) , 105-108
- https://doi.org/10.1111/j.1365-2125.1993.tb04204.x
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- The activation of the biguanide antimalarial proguanil co‐segregates with the mephenytoin oxidation polymorphism‐a panel study.British Journal of Clinical Pharmacology, 1991
- Cloning and expression of complementary DNAs for multiple members of the human cytochrome P450IIC subfamilyBiochemistry, 1991
- In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450 MP) enzyme.British Journal of Clinical Pharmacology, 1990
- Inter‐subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man.British Journal of Clinical Pharmacology, 1989
- Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.British Journal of Clinical Pharmacology, 1989
- Characterization of cDNAs, mRNAs, and proteins related to human liver microsomal cytochrome P-450 S-mephenytoin 4-hydroxylaseBiochemistry, 1988
- Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices.British Journal of Clinical Pharmacology, 1986
- Sparteine Oxidation Polymorphism in DenmarkActa Pharmacologica et Toxicologica, 1985
- Genetic polymorphism of mephenytoin p(4′)‐hydroxylation: difference between Orientals and Caucasians.British Journal of Clinical Pharmacology, 1985
- A Metabolite of ‘Paludrine’ with High Antimalarial ActivityNature, 1951